CNBX stock CNBX Pharmaceuticals Inc. (PNK) $0.0006 08 Jan 2026: Earnings on Jan 12 could move value
CNBX stock trades at $0.0006 on the PNK exchange in the United States as of 08 Jan 2026, with volume surging to 114,115,197 shares today. Investors should note an upcoming earnings announcement on 12 Jan 2026, a likely catalyst for this highly volatile name. This earnings spotlight covers price drivers, visible financial stress points such as EPS -0.01 and PE -0.05, and what to watch in the company’s pipeline and liquidity ahead of the print. We focus on clear metrics, short-term triggers, and the forecast that frames risk and reward
CNBX stock: immediate market snapshot and trading action
CNBX stock opened at $0.0003 and hit a day high of $0.0006 and low of $0.0003 on heavy intraday trading. Market cap is USD 46,256 and shares outstanding are 92,511,300. Average volume sits at 12,500,846, but today’s volume is 114,115,197, reflecting speculative interest. The 50-day average price is $0.0003884 and the 200-day average is $0.00130555, underlining the stock’s long-term downtrend.
CNBX stock earnings: what the Jan 12 report could reveal
CNBX reports earnings on 12 Jan 2026 and the print could trigger large moves given the stock’s low float and high intraday volume. Key items to watch are cash burn, any licensing or partnership updates for lead candidate RCC-33, and guidance on trial timelines. With TTM metrics showing negative operating cash flow per share (-0.0044840771) and book value per share (-0.0595671416), investors will parse liquidity and fundraising plans closely.
CNBX stock financials and valuation metrics
CNBX’s trailing metrics point to distressed fundamentals: EPS -0.01, PE -0.05, and enterprise value roughly USD 1,372,744 versus market cap USD 46,256. Current ratio is 0.0073 and cash per share is 0.0003204 USD, highlighting liquidity strain. Research and development to revenue is high at 4.21 (TTM) while debt-to-assets is 71.99%, indicating leverage relative to reported assets. These exact ratios explain why large institutional ownership is limited and why share price reacts to news and volume.
Meyka AI rates CNBX with a score out of 100 and technical signals
Meyka AI rates CNBX with a score out of 100: 67.80 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry trends, financial growth, key metrics, forecasts, analyst consensus and fundamentals. Technical indicators show an RSI near 62.90 and a high CCI at 209.91, implying short-term momentum but no sustained trend (ADX 15.29). On-chain and social activity appear limited relative to larger biotech names. Note: grades are informational and not financial advice.
CNBX stock risks and opportunities for investors
Primary risks include extreme liquidity shortage, ongoing negative cash flow, and limited operating scale with one full-time employee listed. Upside opportunities stem from any positive clinical readouts, licensing deals for RCC-33 or Cannabics SR, or strategic partnerships amid a busy biotech M&A market. Sector momentum in biotech and Big Pharma buying interest could lift speculative small-caps, but potential dilution is likely if CNBX raises capital to fund trials.
CNBX stock price targets, outlook and scenario analysis
Analyst coverage is thin and there is no consensus price target. We provide scenario targets for context: a conservative 12-month target of $0.0015 (implied upside +150.00%), a bullish scenario at $0.0100 (implied upside +1,566.67%), and a downside scenario at $0.0003 (implied downside -50.00%). These targets reflect outcomes from clinical progress, deals, or continued dilution. For more on catalysts and sector context, see coverage on GLP-1 and biotech M&A trends from CNBC and CNBC. Also see the Meyka stock page for CNBX for live updates: Meyka CNBX page.
Final Thoughts
CNBX stock is exceptionally volatile and trades at USD 0.0006 on the PNK exchange in the United States ahead of its 12 Jan 2026 earnings announcement. Short-term upside depends on any clinical progress, licensing news, or clarity on funding. Financials show clear stress—negative EPS (-0.01), a weak current ratio (0.0073) and minimal cash per share (0.0003204 USD)—which increases dilution risk. Meyka AI’s forecast model projects a 12-month base-case price of $0.0015 versus the current $0.0006, an implied upside of +150.00%; bullish and bearish scenarios widen the range substantially. Forecasts are model-based projections and not guarantees. For traders, the stock offers high reward and high risk: consider position sizing, event-driven timing around the Jan 12 earnings, and watch liquidity and any capital raise announcements closely. Meyka AI provides this analysis as an AI-powered market analysis platform to help frame scenarios, not as financial advice.
FAQs
When does CNBX stock report earnings and why does it matter?
CNBX stock is scheduled to report earnings on 12 Jan 2026. The report matters because it may disclose cash runway, trial updates for RCC-33 and funding plans—information that can swing this low-priced, high-volume name.
What are the main financial risks for CNBX stock?
Major risks for CNBX stock include negative EPS (-0.01), a weak current ratio (0.0073), low cash per share (0.0003204 USD) and likely dilution if management raises capital to fund trials.
How does Meyka AI view CNBX stock and what is the forecast?
Meyka AI rates CNBX with a score of 67.80 (Grade B, Suggestion: HOLD). Meyka AI’s forecast model projects a base-case $0.0015 in 12 months versus current $0.0006. Forecasts are model projections and not guarantees.
What catalysts could move CNBX stock after earnings?
Catalysts include trial progress or positive data for RCC-33, licensing or partnership announcements, clarity on cash runway, and any firm capital raise terms that limit dilution for CNBX stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
